Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice

Journal of Pharmaceutical and Biomedical Analysis

Volumn 56, Issue 5, 2011, Pages 1117-1120

  Nuthalapati, Silpa ^a   Guo, Ping ^a,c   Zhou, Qingyu ^b   Reddy, M V Ramana ^b   Reddy, E Premkumar ^b   Gallo, James M ^b  

^a TEMPLE UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Frontage Laboratories   (United States)

Author keywords

Brain tumor; LC MS MS; ON01910; Pharmacokinetics; Validation

Indexed keywords

ANTINEOPLASTIC AGENT; BENZYL STYRYL SULFONE; SULFONE DERIVATIVE; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; BRAIN TUMOR; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; FECES; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; URINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CALIBRATION; CHROMATOGRAPHY, LIQUID; GLYCINE; LIMIT OF DETECTION; MICE; REPRODUCIBILITY OF RESULTS; SULFONES; TANDEM MASS SPECTROMETRY;

EID: 80052799766     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.08.003     Document Type: Article

References (6)

1. Gumireddy K., Reddy M.V., Cosenza S.C., Boominathan R., Baker S.J., Papathi N., Jiang J., Holland J., Reddy E.P. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005, 7:275-286.
2. Li J., Zhao M., Jimeno A., He P., Ramana Reddy M.V., Hidalgo M., Donehower R.C., Rudek M.A. Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2007, 856:198-204.
3. Chun A.W., Cosenza S.C., Taft D.R., Maniar M. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent. Cancer Chemother. Pharmacol. 2009, 65:177-186.
4. Shah V.P., Midha K.K., Findlay J.W., Hill H.M., Hulse J.D., McGilveray I.J., McKay G., Miller K.J., Patnaik R.N., Powell M.L., Tonelli A., Viswanathan C.T., Yacobi A. Bioanalytical method validation-a revisit with a decade of progress. Pharm. Res. 2000, 17:1551-1557.
5. Lee S.W., Kim W.J., Park J.A., Choi Y.K., Kwon Y.W., Kim K.W. Blood-brain barrier interfaces and brain tumors. Arch. Pharm. Res. 2006, 29:265-275.
6. Gondi C.S., Kandhukuri N., Yanamandra N., Reddy M., Reddy E., Rao J.S. Regression of pre-established intracranial tumor growth by ON 01910.Na, a selective anticancer agent currently in phase I trials. ASCO Annual meeting proceedings. J. Clin. Oncol. 2006, 24:1576.